Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity

By afschroeder • October 13, 2025

Li YR, Shen X, Zhu Y, Li Z, Hon R, Tian Y, Huang J, Zhao AS, Ma NY, Zhang C, Lin D, Sargsyan K, Yuan Y, Yang L. Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity. J Hematol Oncol. 2025 Oct 13;18(1):86. doi: 10.1186/s13045-025-01736-9. PMID: 41077583.

Tags: allogeneic CAR-NKT cells, Allogeneic cell therapy, allorejection, Cedars Sinai DoM, CRISPR-Cas9 gene editing, Hematology/Oncology, HLA ablation, Mesothelin-targeting CAR (MCAR), Metastatic model, Multiple tumor targeting mechanism, Off-the-shelf, Orthotopic model, Potent antitumor activity, Publications, Triple-negative breast cancer (TNBC), tumor microenvironment (TME), Tumor-associated macrophage (TAM)

Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial

McDonald CM, Villa C, Soslow JH, Maharry K, Hogan N, Binks M, Berth KC, Elliott KA, Taylor M, Hor KN, Signorovich J, Henricson EK, Phan[...]

Hidden risk in normal myocardial perfusion scans: AI-detected proximal coronary calcium on CT attenuation maps improves prognosis

Zhou J, Miller RJH, Shanbhag A, Killekar A, Han D, Patel KK, Pieszko K, Yi J, Urs MK, Ramirez G, Lemley M, Kavanagh PB, Liang[...]

Correction to: Consensus and Controversies about Diagnosing GH deficiency – A Delphi Survey by the GH Research Society

Radovick S, Arlien-Søborg MC, Boguszewski MCS, Bidlingmaier M, Johannsson G, Grimberg A, Ho KKY, Biller BMK, Choong CS, Hoffman AR, Backeljauw P, Boguszewski CL, Bollerslev[...]